Page 55 - Read Online

Page 12 of 13 Spieler et al. Hepatoma Res 2019;5:4 I http://dx.doi.org/10.20517/2394-5079.2018.77

20. Hong TS, DeLaney TF, Mamon HJ, Willett CG, Yeap BY, et al. A prospective feasibility study of respiratory-gated proton beam
therapy for liver tumors. Pract Radiat Oncol 2014;4: 316-22.
21. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, et al. Multi-institutional phase II study of high-dose hypofractionated proton
beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol
2016;34:460-8.
22. Gandhi SJ, Liang X, Ding X, Zhu TC, Ben-Josef E, et al. Clinical decision tool for optimal delivery of liver stereotactic body radiation
therapy: photons versus protons. Pract Radiat Oncol 2015;5:209-18.
23. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival
in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016;34:219-26.
24. Fode MM, Høyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases.
Radiother Oncol 2015;114:155-60.
25. Chen X, Liu L, Pan X. Portal vein tumor thrombus in advanced hepatocellular carcinoma: a case report. Oncol Lett 2015;9:2495-8.
26. Xi M, Zhang L, Zhao L, Li QQ, Guo SP, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal
vein and/or inferior vena cava tumor thrombosis. PLoS One 2013;8:e63864.
27. O’Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, et al. Long-term outcomes of stereotactic body radiation therapy in the
treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012;18:949-54.
28. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
Int J Radiat Oncol Biol Phys 2011;81:e447-53.
29. Organ LW. Electrophysiologic principles of radiofrequency lesion making. Appl Neurophysiol 1976-1977;39:69-76.
30. Eisele RM. Advances in local ablation of malignant liver lesions. World J Gastroenterol 2016;22:3885-91.
31. Llovet JM, Real MI, Montaña X, Planas R, Coll S, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in
patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
32. Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol 2013;30:3-11.
33. Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to
transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67:92-9.
34. Su TS, Liang P, Liang J, Lu HZ, Jiang HY, et al. Long-term survival analysis of stereotactic ablative radiotherapy versus liver
resection for small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2017;98:639-46.
35. Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl
2015;21:1142-52.
36. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, et al. Downstaging of hepatocellular cancer before liver transplant: long-term
outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968-77.
37. Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is
associated with improved clinical outcome. Ann Surg Oncol 2014;21:1287-95.
38. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat
Oncol Biol Phys 1979;5:85-91.
39. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, et al. Outcomes after stereotactic body radiotherapy or radiofrequency
ablation for hepatocellular carcinoma. J Clin Oncol 2016;34:452-9.
40. Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, et al. Stereotactic body radiation therapy as an alternative to transarterial
chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2018;100:122-30.
41. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally
advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-9.
42. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a
local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424-31.
43. Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a
single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 2015;141:1301-9.
44. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, et al. Recommendations for radioembolization of hepatic malignancies using
yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium
(REBOC). Int J Radiat Oncol Biol Phys 2007;68:13-23.
45. Johnson DT, Kesner AL. Yttrium-90 selective internal radiation therapy. In: Meyer J, Schefter T, editors. Radiation Therapy for Liver
Tumors. Germany: Springer, Cham; 2017.
46. Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular
carcinoma: european experience on safety and long-term survival. Hepatology 2010;52:1741-9.
47. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, et al. Y90 radioembolization significantly prolongs time to progression compared
with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016;151:1155-63.
48. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, et al. Survival after yttrium-90 resin microsphere radioembolization of
hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868-78.
49. Menon KM, Khosla A, Trimmer CK. Principles of intra-arterial therapies. In: Meyer J, Schefter T, editors. Radiation Therapy for Liver
Tumors. Germany: Springer, Cham; 2017.
50. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, et al. Biliary sequelae following radioembolization with yttrium-90
microspheres. J Vasc Interv Radiol 2008;19:691-7.
51. Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez-Fraile M, et al. Prognostic factors and prevention of
radioembolization-induced liver disease. Hepatology 2013;57:1078-87.
52. Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, et al. Treatment variables related to liver toxicity in patients with
hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat